82491-025-10 : NDC 2026 Code

82491-025-10 : Bevacizumab-vikg ( Lytenava )

Additionally :

You can get information about “82491-025-10” NDC code in 82491-025-10 in HTML format

HTML | 82491-025-10 in TXT (Plain Text) format

TXT | 82491-025-10 in PDF (Portable Document Format)

PDF | 82491-025-10 in XML format

XML formats.

NDC Code : 82491-025-10 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "82491-025-10",
    "PackageDescription": "1 VIAL, GLASS in 1 CARTON (82491-025-10)  / 1 INJECTION in 1 VIAL, GLASS",
    "NDC11Code": "82491-0025-10",
    "ProductNDC": "82491-025",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Lytenava",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Bevacizumab-vikg",
    "DosageFormName": "INJECTION",
    "RouteName": "INTRAVITREAL",
    "StartMarketingDate": "20260716",
    "EndMarketingDate": null,
    "MarketingCategoryName": "BLA",
    "ApplicationNumber": "BLA761320",
    "LabelerName": "Outlook Therapeutics, Inc.",
    "SubstanceName": "BEVACIZUMAB",
    "StrengthNumber": "1.25",
    "StrengthUnit": "mg/1",
    "Pharm_Classes": "Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2026-08-07",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20271231",
    "StartMarketingDatePackage": "20260716",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}